MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Aug 6, 04:59 PM (EDT)
Price
$25.84
Change
-$0.77 (-2.89%)
Net Assets
69.2M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Aug 05, 2025

CANC sees its Stochastic Oscillator climbs out of oversold territory

On August 05, 2025, the Stochastic Oscillator for CANC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 22 instances where the indicator left the oversold zone. In of the 22 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2025. You may want to consider a long position or call options on CANC as a result. In of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 121 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 79 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on July 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CANC broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 44.5B. The market cap for tickers in the group ranges from 3.51M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 29%. For the same ETF, the average monthly price growth was 221%, and the average quarterly price growth was 261%. REPL experienced the highest price growth at 69%, while ILMN experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -25%. For the same stocks of the ETF, the average monthly volume growth was 48% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 79
Price Growth Rating: 56
SMR Rating: 77
Profit Risk Rating: 80
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co